Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research ...

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...

Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Sea-based launches are hitting their stride. That could lead to a lot more space missions with a lot less red tape. What will really matter in the long run? That’s the question we tackle each year as ...

The chip maker is likely to be watching OpenAI after a consortium headed by Elon Musk offered almost $100 billion for the ...

Precision Medicine Is the Future Of Healthcare When it comes to applied hard sciences, a source of progress has been more precise measurements and tools. This is especially true in physics and ...

ABC News’ Alexis Christoforous reports on what Fed Chair Jerome Powell is telling lawmakers about a “strong overall” economy.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...